Hepatitis Monthly

Published by: Kowsar

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta

Maryam Keshvari 1 , 2 , Seyed Moayed Alavian 2 , * , Heidar Sharafi 2 , Gharib Karimi 1 and Mohammad Gholami Fesharaki 3
Authors Information
1 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine,Tehran, IR Iran
2 Middle East Liver Disease (MELD) Center, Tehran, IR Iran
3 Department of Biostatistics, School of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
Article information
  • Hepatitis Monthly: March 01, 2014, 14 (3); e15729
  • Published Online: March 1, 2014
  • Article Type: Research Article
  • Received: October 28, 2013
  • Revised: December 4, 2013
  • Accepted: January 22, 2014
  • DOI: 10.5812/hepatmon.15729

To Cite: Keshvari M, Alavian S M, Sharafi H, Karimi G, Gholami Fesharaki M. et al. Interferon Alpha-2b Therapy in Chronic Hepatitis Delta, Hepat Mon. 2014 ;14(3):e15729. doi: 10.5812/hepatmon.15729.

Abstract
Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977; 18(12): 997-1003[PubMed]
  • 2. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011; 364(4): 322-31[DOI][PubMed]
  • 3. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011; 378(9785): 73-85[DOI][PubMed]
  • 4. Husa P, Linhartova A, Nemecek V, Husova L. Hepatitis D. Acta Virol. 2005; 49(4): 219-25[PubMed]
  • 5. Alavian S, Alavian S. Hepatitis D Virus Infection; Iran, Middle East and Central Asia. Hepat Mon. 2005; : 137-43
  • 6. Yurdaydin C, Bozkaya H, Karaaslan H, Onder FO, Erkan OE, Yalcin K, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat. 2007; 14(11): 812-6[DOI][PubMed]
  • 7. Farci P, Chessa L, Balestrieri C, Serra G, Lai ME. Treatment of chronic hepatitis D. J Viral Hepat. 2007; 14 Suppl 1: 58-63[DOI][PubMed]
  • 8. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology. 1994; 19(6): 1331-6[PubMed]
  • 9. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010; 17(11): 749-56[DOI][PubMed]
  • 10. Smedile A, Niro MG, Rizzetto M. Detection of serum HDV RNA by RT-PCR. Methods Mol Med. 2004; 95: 85-93[DOI][PubMed]
  • 11. Gheorghe L, Iacob S, Simionov I, Vadan R, Constantinescu I, Caruntu F, et al. Weight-based dosing regimen of peg-interferon alpha-2b for chronic hepatitis delta: a multicenter Romanian trial. J Gastrointestin Liver Dis. 2011; 20(4): 377-82[PubMed]
  • 12. Ho E, Deltenre P, Nkuize M, Delwaide J, Colle I, Michielsen P, et al. Coinfection of hepatitis B and hepatitis delta virus in Belgium: a multicenter BASL study. Prospective epidemiology and comparison with HBV mono-infection. J Med Virol. 2013; 85(9): 1513-7[DOI][PubMed]
  • 13. Kaymakoglu S, Karaca C, Demir K, Poturoglu S, Danalioglu A, Badur S, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother. 2005; 49(3): 1135-8[DOI][PubMed]
  • 14. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010; 53(5): 834-40[DOI][PubMed]
  • 15. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994; 330(2): 88-94[DOI][PubMed]
  • 16. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 1995; 15(1): 45-52[PubMed]
  • 17. Lau JY, King R, Tibbs CJ, Catterall AP, Smith HM, Portmann BC, et al. Loss of HBsAg with interferon-alpha therapy in chronic hepatitis D virus infection. J Med Virol. 1993; 39(4): 292-6[PubMed]
  • 18. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, Di Bisceglie AM. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol. 1994; 44(4): 389-92[PubMed]
  • 19. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology. 1991; 13(6): 1052-6[PubMed]
  • 20. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005; 10(6): 721-6[PubMed]
  • 21. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, Akdogan M, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008; 15(4): 314-21[DOI][PubMed]
  • 22. Gulsun S, Tekin R, Bozkurt F. Treatment of chronic delta hepatitis: a nine-year retrospective analysis. Hepat Mon. 2011; 11(9): 731-5[DOI][PubMed]
  • 23. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004; 126(7): 1740-9[PubMed]
  • 24. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006; 44(3): 713-20[DOI][PubMed]
  • 25. Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev. 2011; (12)[DOI][PubMed]
  • 26. Brichler S, Setshedi M, Renou C. Resolution of chronic hepatitis delta infection after five years of peginterferon-adefovir: lessons from a case report. Clin Res Hepatol Gastroenterol. 2013; 37(3)-4[DOI][PubMed]
  • 27. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999; 117(5): 1229-33[PubMed]
  • 28. Alavian SM, Tabatabaei SV, Behnava B, Rizzetto M. Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis. J Res Med Sci. 2012; 17(10): 967-74[PubMed]
  • 29. Karaca C, Soyer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, et al. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. 2013; 18(4): 561-6[DOI][PubMed]
  • 30. Lamers MH, Kirgiz OO, Heidrich B, Wedemeyer H, Drenth JP. Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012; 17(6): 1029-37[DOI][PubMed]
  • 31. Mansour W, Ducancelle A, Le Gal F, Le Guillou-Guillemette H, Abgueguen P, Pivert A, et al. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol. 2010; 47(1): 97-9[DOI][PubMed]
  • 32. Dastgerdi ES, Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. World J Virol. 2012; 1(3): 71-8[DOI][PubMed]
  • 33. Hadziyannis SJ. Use of alpha-interferon in the treatment of chronic delta hepatitis. J Hepatol. 1991; 13 Suppl 1-6[PubMed]
  • 34. Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013; 28(9): 1521-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments